We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Otorhinolaryngology

Otorhinolaryngology

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

Long-Term Survival Gains with Tislelizumab: Redefining First-Line Therapy for Metastatic Nasopharyngeal Carcinoma
newsimmunotherapynasopharyngeal carcinoma

Long-Term Survival Gains with Tislelizumab: Redefining First-Line Therapy for Metastatic Nasopharyngeal Carcinoma

By MedXY|Mar 9, 2026

The 3-year follow-up of the RATIONALE-309 trial demonstrates that first-line tislelizumab plus chemotherapy significantly improves overall survival (45.3 months) in recurrent or metastatic nasopharyngeal carcinoma, identifying B-cell signat

Surgical Management of Sporadic Medullary Thyroid Cancer: Evidence-Based Comparison of Total Thyroidectomy vs Lobectomy
Clinical UpdatesLobectomymedullary thyroid carcinoma

Surgical Management of Sporadic Medullary Thyroid Cancer: Evidence-Based Comparison of Total Thyroidectomy vs Lobectomy

By MedXY|Mar 2, 2026

This systematic review and meta-analysis suggests that thyroid lobectomy may offer comparable oncologic outcomes to total thyroidectomy for selected patients with sporadic medullary thyroid cancer, while significantly reducing postoperative

Beyond Objective Responses: Amivantamab Demonstrates Significant Clinical Benefit in Recurrent Adenoid Cystic Carcinoma
newsamivantamabtargeted therapy

Beyond Objective Responses: Amivantamab Demonstrates Significant Clinical Benefit in Recurrent Adenoid Cystic Carcinoma

By MedXY|Mar 2, 2026

A Phase 2 clinical trial of amivantamab, an EGFR-MET bispecific antibody, in recurrent or metastatic adenoid cystic carcinoma (ACC) showed a 72.2% clinical benefit rate. While the primary objective response rate was low, the high rate of di

Three-Year RATIONALE-309 Data Confirm Sustained Survival Benefit of First-Line Tislelizumab in Nasopharyngeal Carcinoma
newsimmunotherapynasopharyngeal carcinoma

Three-Year RATIONALE-309 Data Confirm Sustained Survival Benefit of First-Line Tislelizumab in Nasopharyngeal Carcinoma

By MedXY|Mar 2, 2026

Long-term results from the RATIONALE-309 trial show tislelizumab plus chemotherapy significantly improves survival in recurrent or metastatic nasopharyngeal carcinoma, establishing a durable therapeutic standard and identifying B-cell signa

Redefining the Standard of Care in High-Risk Resected SCCHN: Insights from the GORTEC 2018-01 NIVOPOST-OP Trial
Clinical Updateshead and neck cancerimmunotherapy

Redefining the Standard of Care in High-Risk Resected SCCHN: Insights from the GORTEC 2018-01 NIVOPOST-OP Trial

By MedXY|Mar 2, 2026

This review analyzes the Phase 3 NIVOPOST-OP trial, demonstrating that adding nivolumab to postoperative chemoradiotherapy significantly improves disease-free survival in high-risk SCCHN patients, establishing a potential new therapeutic st

Optimizing Prognosis: The New AJCC Version 9 Staging for Salivary Gland Carcinoma
newsoncologySalivary Gland Carcinoma

Optimizing Prognosis: The New AJCC Version 9 Staging for Salivary Gland Carcinoma

By MedXY|Feb 20, 2026

The proposed AJCC/UICC Version 9 staging for salivary gland carcinoma shifts toward a unified, specific system using lymph node count and extranodal extension, significantly improving prognostic accuracy for both major and minor salivary gl

Pembrolizumab Dominates the HNC Market While Immune-Related Adverse Events Persist in Real-World Practice
newsadverse eventshead and neck cancer

Pembrolizumab Dominates the HNC Market While Immune-Related Adverse Events Persist in Real-World Practice

By MedXY|Feb 19, 2026

A large-scale cohort study of 47,365 head and neck cancer patients reveals a significant market shift toward pembrolizumab and a 41.2% incidence of immune-related adverse events, though severe toxicities remain rare and are linked to specif

PTH-Guided Selective Calcium Supplementation After Total Thyroidectomy: Is Routine Prophylaxis Still Necessary?
General SurgeryendocrinologyHypocalcemia

PTH-Guided Selective Calcium Supplementation After Total Thyroidectomy: Is Routine Prophylaxis Still Necessary?

By MedXY|Feb 19, 2026

A multicenter randomized clinical trial demonstrates that selective calcium supplementation based on early postoperative PTH levels is as effective as routine prophylaxis in preventing hypocalcemia after total thyroidectomy, offering a stra

Thyroidectomy in Older Adults: Are Increased Relative Risks a Barrier to Surgical Safety?
General Surgerypatient safetythyroidectomy

Thyroidectomy in Older Adults: Are Increased Relative Risks a Barrier to Surgical Safety?

By MedXY|Feb 8, 2026

A systematic review and meta-analysis of over 400,000 patients reveals that while older adults face higher relative risks for nerve injury and hematoma following thyroidectomy, the absolute risk remains low, confirming the procedure’s

Camrelizumab Plus Chemotherapy Sets a New Five-Year Survival Benchmark in Recurrent or Metastatic Nasopharyngeal Carcinoma
newscamrelizumabimmunotherapy

Camrelizumab Plus Chemotherapy Sets a New Five-Year Survival Benchmark in Recurrent or Metastatic Nasopharyngeal Carcinoma

By MedXY|Jan 30, 2026

A secondary analysis of the CAPTAIN-1st trial reveals that adding camrelizumab to first-line chemotherapy significantly improves five-year overall survival in RM-NPC, with a 37.8% survival rate and notable benefits linked to rapid EBV DNA c

The Precision Gap: Evaluating Sentinel Lymph Node Biopsy in Head and Neck Merkel Cell Carcinoma
newshead and neck cancerMerkel Cell Carcinoma

The Precision Gap: Evaluating Sentinel Lymph Node Biopsy in Head and Neck Merkel Cell Carcinoma

By MedXY|Jan 30, 2026

This article examines the clinical accuracy of Sentinel Lymph Node Biopsy for head and neck Merkel cell carcinoma, highlighting a significant false-negative rate and identifying risk factors that necessitate more personalized treatment stra

Optimizing the Surgical Field: Diltiazem and Esmolol Excel in Controlled Hypotension for Endoscopic Sinus Surgery
Anesthesiologyanesthesiologydexmedetomidine

Optimizing the Surgical Field: Diltiazem and Esmolol Excel in Controlled Hypotension for Endoscopic Sinus Surgery

By MedXY|Jan 30, 2026

This systematic review and network meta-analysis of 52 randomized trials evaluates pharmacological agents for controlled hypotension in ESS, identifying diltiazem, esmolol, and dexmedetomidine as the most effective for reducing intraoperati

Intensity-Modulated Proton Therapy Reduces Acute Toxicity While Maintaining Oncologic Equivalence in Nasopharyngeal Carcinoma: A Five-Year Case-Control Analysis
newsIMRTnasopharyngeal carcinoma

Intensity-Modulated Proton Therapy Reduces Acute Toxicity While Maintaining Oncologic Equivalence in Nasopharyngeal Carcinoma: A Five-Year Case-Control Analysis

By MedXY|Jan 29, 2026

A case-control study comparing IMPT and IMRT for nasopharyngeal carcinoma shows that IMPT significantly reduces grade 2+ acute toxicities without compromising long-term survival or local-regional control, suggesting a superior therapeutic i

Beyond the Binary: A New 4-Stage Stratification System Revolutionizes Cochlear Implant Candidacy Assessment
newsaudiometryCochlear Implants

Beyond the Binary: A New 4-Stage Stratification System Revolutionizes Cochlear Implant Candidacy Assessment

By MedXY|Jan 27, 2026

Researchers have developed a 4-level classification system using routine audiometric data to estimate cochlear implant candidacy likelihood. This tool moves beyond traditional binary screening, providing a probability gradient that enhances

Intranasal Saline Matches Steroids in Pediatric Sleep-Disordered Breathing: Rethinking the First-Line Approach
newssleep apnea

Intranasal Saline Matches Steroids in Pediatric Sleep-Disordered Breathing: Rethinking the First-Line Approach

By MedXY|Jan 26, 2026

The MIST+ trial demonstrates that intranasal saline is as effective as mometasone for pediatric sleep-disordered breathing, suggesting a conservative 3-month saline trial can resolve symptoms in half of patients and potentially reduce the n

Beyond the Scalpel: How ctDNA Blood Tests are Revolutionizing Head and Neck Cancer Monitoring
newsctDNAhead and neck cancer

Beyond the Scalpel: How ctDNA Blood Tests are Revolutionizing Head and Neck Cancer Monitoring

By MedXY|Jan 25, 2026

A new study reveals that ‘tumor-informed’ blood tests can detect recurring head and neck cancer months before traditional scans, offering a critical window for intervention in high-risk patients.

The Changing Landscape of Acute Invasive Fungal Rhinosinusitis: Rising Detection and Declining Mortality
Infectious DiseasesAIFRSimmunocompromised

The Changing Landscape of Acute Invasive Fungal Rhinosinusitis: Rising Detection and Declining Mortality

By MedXY|Jan 25, 2026

A landmark systematic review of over 48,000 patients reveals that while the proportion of AIFRS in immunocompromised populations is increasing, mortality rates have dropped significantly since 2013 due to diagnostic and therapeutic advancem

AIFRS Mortality Drops as Detection Rates Climb: New Insights into Acute Invasive Fungal Rhinosinusitis
Infectious DiseasesAIFRSimmunocompromised

AIFRS Mortality Drops as Detection Rates Climb: New Insights into Acute Invasive Fungal Rhinosinusitis

By MedXY|Jan 25, 2026

A comprehensive meta-analysis reveals that while the proportion of AIFRS in immunocompromised patients has risen to 16.6% in recent years, mortality has significantly decreased to 28.2% due to improved diagnostic and therapeutic strategies.

New Gold Standard for Olfactory Assessment: Validating the Hebrew ‘Sniffin’ Sticks’ Test
newsolfactory dysfunction

New Gold Standard for Olfactory Assessment: Validating the Hebrew ‘Sniffin’ Sticks’ Test

By MedXY|Jan 18, 2026

Researchers have validated a Hebrew version of the ‘Sniffin’ Sticks’ identification test, providing a highly reliable and culturally adapted tool for diagnosing olfactory dysfunction in Israel with a sensitivity of 93.3%.

Sniffing Out Health: How a New Smartphone App Could Revolutionize Smell Testing
newsdigital healthMedical Screening

Sniffing Out Health: How a New Smartphone App Could Revolutionize Smell Testing

By MedXY|Jan 18, 2026

Researchers have developed a rapid, 5-item mobile application-based test to screen for olfactory dysfunction, offering a high-accuracy, low-cost alternative to traditional diagnostic methods for a condition often linked to aging and neurolo

Prev
8 / 13
1…678910…13
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities

Browse by specialty

Open language-specific specialty feeds and department pages.

news6629 articlesCardiology1375 articlesClinical Updates1288 articlesOncology1139 articlesDiabetes & Endocrinology842 articlesNeurology820 articlesPublic Health595 articlesGastroenterology572 articles
Hematology-Oncology
487 articles
Pediatrics484 articles
Internal Medicine444 articles